Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 15 | 2024 | 1130 | 3.420 |
Why?
|
| Lung Neoplasms | 18 | 2024 | 2368 | 3.170 |
Why?
|
| Advance Care Planning | 2 | 2018 | 45 | 1.140 |
Why?
|
| Radiosurgery | 4 | 2024 | 287 | 1.090 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 48 | 0.820 |
Why?
|
| Piperidines | 2 | 2022 | 163 | 0.810 |
Why?
|
| Neoplasms | 5 | 2022 | 3062 | 0.790 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 2328 | 0.790 |
Why?
|
| Immunotherapy | 4 | 2022 | 693 | 0.750 |
Why?
|
| Carbazoles | 1 | 2020 | 33 | 0.690 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 158 | 0.550 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 364 | 0.550 |
Why?
|
| Survival Analysis | 1 | 2018 | 1497 | 0.470 |
Why?
|
| Stress, Psychological | 2 | 2014 | 322 | 0.460 |
Why?
|
| Heart Arrest | 1 | 2017 | 278 | 0.450 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 208 | 0.440 |
Why?
|
| Health Expenditures | 1 | 2014 | 90 | 0.440 |
Why?
|
| Disclosure | 1 | 2014 | 109 | 0.430 |
Why?
|
| Medical Oncology | 1 | 2017 | 384 | 0.430 |
Why?
|
| Thoracic Neoplasms | 2 | 2023 | 66 | 0.410 |
Why?
|
| Prognosis | 3 | 2022 | 3789 | 0.400 |
Why?
|
| Humans | 28 | 2024 | 89864 | 0.400 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 112 | 0.350 |
Why?
|
| Pyrimidines | 2 | 2024 | 371 | 0.350 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1542 | 0.350 |
Why?
|
| Mutation | 6 | 2024 | 4164 | 0.340 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 490 | 0.340 |
Why?
|
| Algorithms | 1 | 2018 | 1908 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 586 | 0.280 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 165 | 0.260 |
Why?
|
| United States | 4 | 2024 | 7094 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2505 | 0.230 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 65 | 0.220 |
Why?
|
| Medication Adherence | 2 | 2014 | 140 | 0.210 |
Why?
|
| Chylothorax | 1 | 2022 | 10 | 0.210 |
Why?
|
| Chylous Ascites | 1 | 2022 | 9 | 0.210 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.200 |
Why?
|
| Pyridazines | 1 | 2022 | 21 | 0.200 |
Why?
|
| Piperazines | 1 | 2024 | 283 | 0.200 |
Why?
|
| Decision Making | 2 | 2018 | 669 | 0.200 |
Why?
|
| Pyridines | 1 | 2024 | 300 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2024 | 919 | 0.190 |
Why?
|
| Ipilimumab | 1 | 2021 | 60 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2023 | 191 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.180 |
Why?
|
| Pneumonia | 1 | 2022 | 183 | 0.180 |
Why?
|
| Medicare | 1 | 2024 | 427 | 0.180 |
Why?
|
| Genetic Testing | 1 | 2024 | 541 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2023 | 9185 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2020 | 95 | 0.160 |
Why?
|
| Biopsy | 1 | 2023 | 1184 | 0.160 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 624 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2021 | 332 | 0.160 |
Why?
|
| Pneumonectomy | 1 | 2021 | 211 | 0.160 |
Why?
|
| Disease Progression | 1 | 2023 | 1469 | 0.150 |
Why?
|
| Genomics | 1 | 2024 | 776 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 605 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 755 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 19230 | 0.140 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 177 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 783 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 306 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 979 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 848 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 175 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 290 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 476 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 394 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 222 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1729 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 279 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 63 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 665 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 387 | 0.110 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 16 | 0.110 |
Why?
|
| Chicago | 1 | 2018 | 1431 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2023 | 43 | 0.110 |
Why?
|
| Caregivers | 1 | 2014 | 167 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 234 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 236 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 466 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6779 | 0.090 |
Why?
|
| Female | 4 | 2021 | 46529 | 0.090 |
Why?
|
| Risk Factors | 2 | 2021 | 5548 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1350 | 0.070 |
Why?
|
| Male | 3 | 2021 | 42614 | 0.060 |
Why?
|
| North America | 1 | 2023 | 188 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 152 | 0.050 |
Why?
|
| Platinum | 1 | 2023 | 64 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.050 |
Why?
|
| Middle Aged | 2 | 2021 | 26103 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 23 | 0.050 |
Why?
|
| Taxoids | 1 | 2023 | 124 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 268 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 56 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 178 | 0.050 |
Why?
|
| Netherlands | 1 | 2021 | 24 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 191 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 108 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 173 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 165 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2024 | 498 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 311 | 0.040 |
Why?
|
| China | 1 | 2021 | 235 | 0.040 |
Why?
|
| Exons | 1 | 2022 | 453 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 278 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 278 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 149 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 1704 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 727 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1394 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1898 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 2000 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 803 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 1774 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1221 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1665 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2886 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1858 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3670 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 4322 | 0.030 |
Why?
|
| Adult | 1 | 2021 | 26784 | 0.010 |
Why?
|